HEATHER MECOM: Open Payments
NPI 1770005423 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,461 in 220 payments from 28 companies in 2025. Trend: 2023 $3,047 · 2024 $3,077 · 2025 $4,461
Food & beverage: $3,786Consulting: $675
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 11 | $816 |
| ABBVIE INC. | 34 | $557 |
| UCB, Inc. | 14 | $421 |
| Neurocrine BioSciences, Inc. | 40 | $372 |
| Novartis Pharmaceuticals Corporation | 14 | $253 |
| Biogen, Inc. | 10 | $229 |
| EMD Serono, Inc. | 7 | $205 |
| Genentech USA, Inc. | 10 | $199 |
| ARGENX US, INC. | 8 | $176 |
| ACADIA Pharmaceuticals Inc | 28 | $166 |
Products named: NURTEC ODT, INGREZZA, QULIPTA, KESIMPTA, Nayzilam, Ocrevus Zunovo, VYVGART HYTRULO, NUPLAZID.
Industry payments across LA — which companies pay providers there.
